Weight ManagementJuly 26, 2026·4 min read
By the CIRRUS Editorial Team — how we write and source this
GLP-1 drugs measurably reduce sleep apnea severity — here's the actual AHI data
Tirzepatide trials in obstructive sleep apnea reported meaningful drops in the Apnea-Hypopnea Index, but they didn't eliminate the diagnosis for most participants.
Obesity is the single largest modifiable risk factor for obstructive sleep apnea, since excess tissue around the airway increases collapse risk during sleep. Trial data on tirzepatide in patients with moderate-to-severe OSA and obesity showed average AHI reductions in the range of 50-60% over roughly a year of treatment — a substantial improvement by any measure, but for most participants the AHI dropped into a lower severity category rather than to zero.
That distinction matters for anyone hoping GLP-1 therapy will let them stop CPAP entirely. A large AHI reduction can mean a genuine downgrade from severe to mild OSA, which changes quality of life and cardiovascular risk meaningfully — but 'improved' and 'resolved' are different outcomes, and stopping CPAP without a follow-up sleep study to confirm the new AHI is not something a specialist would recommend.
The practical sequence clinicians increasingly follow: continue CPAP through the weight-loss period, then repeat a sleep study once weight has stabilized to determine whether therapy can be reduced, switched to a lower pressure setting, or in some cases discontinued under medical supervision.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.